ICAM1 and COVID-19: Our results demonstrate that COVID-19 driven cytotoxicity is cell selective not resulting in impaired endothelial cell viability but resulting in cellular activation and upregulation of ICAM-1 with subsequent immune cell adhesion and vWF deposition in the extracellular matrix.